Sophia Antipolis, 27 March 2023: Patients with atrial fibrillation (AF) benefit from early rhythm control therapy. It reduces cardiovascular deaths, strokes, and other adverse outcomes by 20% compared ...

Please provide your email address to receive an email when new articles are posted on . An updated guideline on the prevention and management of atrial fibrillation includes a new staging system to ...

Key takeawaysAn international panel of more than 80 experts has issued updated guidance to improve care for atrial fibrillation (AF) patients ...

The American College of Cardiology (ACC) and the American Heart Association (AHA), along with several other leading medical associations, have issued a new guideline for preventing and optimally ...

AP31969 is a novel, first-in-class, oral SK ion channel inhibitor intended for rhythm control of atrial fibrillation and has recently completed Phase 1 in healthy volunteers ...

Old concerns about the safety of rhythm control drugs for atrial fibrillation (Afib or AF) resurfaced in a contemporary large Korean population-based study. Afib patients prescribed antiarrhythmic ...

The heart rhythm disorder called atrial fibrillation (AFib) can affect people of any age, but is most common in older adults. It may start with a rapid heartbeat, a fluttering feeling in a person’s ...

HUYABIO International today announced favorable Phase 1 clinical data for HBI-3000, a novel bioinspired investigational drug with promising antiarrhythmic properties, excellent tolerability and a ...

The MarketWatch News Department was not involved in the creation of this content. During National Atrial Fibrillation Awareness Month, StopAfib.org urges people to raise atrial fibrillation awareness.

Contrary to old beliefs, a new study suggests daily coffee might help manage irregular heart rhythms like AFib. Researchers found participants drinking coffee experienced fewer episodes compared to ...

The American College of Cardiology (ACC) and the American Heart Association (AHA), along with several other leading medical associations, have issued a new guideline for preventing and optimally ...

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.